Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Depreciation & Amortization (CF): 2012-2024

Historic Depreciation & Amortization (CF) for Ultragenyx Pharmaceutical (RARE) over the last 13 years, with Dec 2024 value amounting to $35.5 million.

  • Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) fell 1.72% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 1.76%. This contributed to the annual value of $35.5 million for FY2024, which is 36.67% up from last year.
  • Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) amounted to $35.5 million in FY2024, which was up 36.67% from $26.0 million recorded in FY2023.
  • In the past 5 years, Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) ranged from a high of $35.5 million in FY2024 and a low of $12.3 million during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $26.6 million, with a median of $26.0 million in 2023.
  • Data for Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) shows a peak YoY soared of 43.59% (in 2020) over the last 5 years.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) (Yearly) stood at $12.3 million in 2020, then increased by 7.98% to $13.2 million in 2021, then soared by 37.62% to $18.2 million in 2022, then soared by 42.73% to $26.0 million in 2023, then spiked by 36.67% to $35.5 million in 2024.